Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer

J. V. Sitzmann, S. E. Order, J. L. Klein, P. K. Leichner, Elliot K Fishman, G. W. Smith

Research output: Contribution to journalArticle

Abstract

Eleven patients with hepatocellular cancer had nonresectable lesions, ten as determined by laparotomy and one by computed tomographic (CT) evidence of inferior vena caval invasion. These patients were treated with a variety of new modalities, particularly radiolabeled antiferritin antibodies. Following treatment, seven of the 11 patients were considered to have converted their lesions to possible resectability. Six patients had complete resections, and one patient was partially resected. All patients had the common features of either nodular massive or nodular multifocal hepatocellular cancer. Relative to the patient's initial status, the quality of life remains high, and a new approach in the treatment of the nodular form of nonresectable hepatoma has been demonstrated. The present rate of such conversion to resectability is unknown. However, with further advances in radiolabeled antibody therapy, these results offer a new opportunity in the management of hepatocellular cancer.

Original languageEnglish (US)
Pages (from-to)1566-1573
Number of pages8
JournalJournal of Clinical Oncology
Volume5
Issue number10
StatePublished - 1987

Fingerprint

Liver Neoplasms
Therapeutics
Venae Cavae
Antibodies
Laparotomy
Hepatocellular Carcinoma
Quality of Life

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sitzmann, J. V., Order, S. E., Klein, J. L., Leichner, P. K., Fishman, E. K., & Smith, G. W. (1987). Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer. Journal of Clinical Oncology, 5(10), 1566-1573.

Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer. / Sitzmann, J. V.; Order, S. E.; Klein, J. L.; Leichner, P. K.; Fishman, Elliot K; Smith, G. W.

In: Journal of Clinical Oncology, Vol. 5, No. 10, 1987, p. 1566-1573.

Research output: Contribution to journalArticle

Sitzmann, JV, Order, SE, Klein, JL, Leichner, PK, Fishman, EK & Smith, GW 1987, 'Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer', Journal of Clinical Oncology, vol. 5, no. 10, pp. 1566-1573.
Sitzmann, J. V. ; Order, S. E. ; Klein, J. L. ; Leichner, P. K. ; Fishman, Elliot K ; Smith, G. W. / Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer. In: Journal of Clinical Oncology. 1987 ; Vol. 5, No. 10. pp. 1566-1573.
@article{5a3593da0f434a0193a9f8ddbd022873,
title = "Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer",
abstract = "Eleven patients with hepatocellular cancer had nonresectable lesions, ten as determined by laparotomy and one by computed tomographic (CT) evidence of inferior vena caval invasion. These patients were treated with a variety of new modalities, particularly radiolabeled antiferritin antibodies. Following treatment, seven of the 11 patients were considered to have converted their lesions to possible resectability. Six patients had complete resections, and one patient was partially resected. All patients had the common features of either nodular massive or nodular multifocal hepatocellular cancer. Relative to the patient's initial status, the quality of life remains high, and a new approach in the treatment of the nodular form of nonresectable hepatoma has been demonstrated. The present rate of such conversion to resectability is unknown. However, with further advances in radiolabeled antibody therapy, these results offer a new opportunity in the management of hepatocellular cancer.",
author = "Sitzmann, {J. V.} and Order, {S. E.} and Klein, {J. L.} and Leichner, {P. K.} and Fishman, {Elliot K} and Smith, {G. W.}",
year = "1987",
language = "English (US)",
volume = "5",
pages = "1566--1573",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer

AU - Sitzmann, J. V.

AU - Order, S. E.

AU - Klein, J. L.

AU - Leichner, P. K.

AU - Fishman, Elliot K

AU - Smith, G. W.

PY - 1987

Y1 - 1987

N2 - Eleven patients with hepatocellular cancer had nonresectable lesions, ten as determined by laparotomy and one by computed tomographic (CT) evidence of inferior vena caval invasion. These patients were treated with a variety of new modalities, particularly radiolabeled antiferritin antibodies. Following treatment, seven of the 11 patients were considered to have converted their lesions to possible resectability. Six patients had complete resections, and one patient was partially resected. All patients had the common features of either nodular massive or nodular multifocal hepatocellular cancer. Relative to the patient's initial status, the quality of life remains high, and a new approach in the treatment of the nodular form of nonresectable hepatoma has been demonstrated. The present rate of such conversion to resectability is unknown. However, with further advances in radiolabeled antibody therapy, these results offer a new opportunity in the management of hepatocellular cancer.

AB - Eleven patients with hepatocellular cancer had nonresectable lesions, ten as determined by laparotomy and one by computed tomographic (CT) evidence of inferior vena caval invasion. These patients were treated with a variety of new modalities, particularly radiolabeled antiferritin antibodies. Following treatment, seven of the 11 patients were considered to have converted their lesions to possible resectability. Six patients had complete resections, and one patient was partially resected. All patients had the common features of either nodular massive or nodular multifocal hepatocellular cancer. Relative to the patient's initial status, the quality of life remains high, and a new approach in the treatment of the nodular form of nonresectable hepatoma has been demonstrated. The present rate of such conversion to resectability is unknown. However, with further advances in radiolabeled antibody therapy, these results offer a new opportunity in the management of hepatocellular cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023492015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023492015&partnerID=8YFLogxK

M3 - Article

C2 - 2443620

AN - SCOPUS:0023492015

VL - 5

SP - 1566

EP - 1573

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -